Lund based BioInvent has had a busy week with a presentation of one program in ovarian cancer at ASCO, and two more coming up in hematological cancers at the upcoming EHA Congress
- Jun 9
- 1 min read
Chief Scientific Officer Björn Frendéus walks us through the companies antibody discovery platform, and the two lead clinical assets, which target TNFR2 and FcγRIIB.











.png)